HAWTHORNE, N.Y.--(BUSINESS WIRE)-- Taro Pharmaceutical Industries Ltd. (NYS: TARO) ("Taro") reported today that it has received approval from the U.S. Food and Drug Administration ("FDA") for its New ...
Taro Pharmaceuticals announced that it has received approval from the FDA for its New Drug Application (NDA) for Topicort (desoximetasone) Topical Spray. Topicort is a corticosteroid indicated for the ...
Desoximetasone 0.25%. Avoid use on eyes, face, axilla, or groin. Do not use on pre-existing skin atrophy. Risk of HPA axis suppression with high-potency steroids, prolonged use, application to large ...
MUMBAI and BALTIMORE — Lupin recently introduced its generic of Taro’s Topicort LP Emollient Cream and Topicort Cream (desoximetasone cream 0.05% and desoximetasone cream 0.25%). The treatments are ...
Lupin has received final approval for its Desoximetasone cream USP, 0.05 percent and Desoximetasone cream USP, 0.25 percent from the USFDA to market a generic equivalent of Taro Pharmaceuticals North ...
Lupin has received final approval for its Desoximetasone Ointment USP, 0.05 percent from the USFDA to market a generic version of Taro Pharms North's Topicort Ointment 0.05 percent. It has come to our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results